Robbins Farley’s Definium Therapeutics DFTX Stock Holding History

Robbins Farley’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32K	Hold	28	–	–	﹤0.01%	133
2026 Q1	$530	Hold	28	–	–	﹤0.01%	125
2025 Q4	$375	Hold	28	–	–	﹤0.01%	133
2025 Q3	$331	Hold	28	–	–	﹤0.01%	160
2025 Q2	$182	Hold	28	–	–	﹤0.01%	164
2025 Q1	$164	Hold	28	–	–	﹤0.01%	147
2024 Q4	$195	Hold	28	–	–	﹤0.01%	146
2024 Q3	$160	Hold	28	–	–	﹤0.01%	145
2024 Q2	$202	Hold	28	–	–	﹤0.01%	157
2024 Q1	$264	Hold	28	–	–	﹤0.01%	156
2023 Q4	$103	Hold	28	–	–	﹤0.01%	166
2023 Q3	$88	Buy	+28	New	+$115	﹤0.01%	178
2023 Q2	–	Sell	-28	Closed	-$89	–	186
2023 Q1	$89	Hold	28	–	–	﹤0.01%	191
2022 Q4	$62	Hold	28	–	–	﹤0.01%	181
2022 Q3	$0	Buy	+28	New	+$269	﹤0.01%	154
2022 Q2	–	Sell	-23	Closed	–	–	152
2022 Q1	$0	Buy	23 +8	+53%	+$139	﹤0.01%	162
2021 Q4	$0	Buy	15 +7	+88%	+$223	﹤0.01%	194
2021 Q3	$0	Buy	+8	New	+$346	﹤0.01%	181

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Robbins Farley's DFTX Position: Q2 2026 in Review

Robbins Farley held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 28 shares worth $1.32K. The position accounts for ﹤0.01% of the portfolio, ranked #133.

Robbins Farley first reported a position in DFTX in Q3 2021 and has held it in 18 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Robbins Farley held 28 shares of Definium Therapeutics worth $1.32K as of Q2 2026.
Robbins Farley left its Definium Therapeutics share count unchanged in Q2 2026.
Definium Therapeutics made up ﹤0.01% of Robbins Farley's portfolio in Q2 2026, its #133 holding.
Robbins Farley first reported a position in Definium Therapeutics in Q3 2021 and has held it in 18 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Robbins Farley's 13F filing for Q2 2026, filed 23 Jul 2026.